12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention

Metabolic Evaluation & Dietary/Medical Stone Prevention

Effective medical management of urolithiasis requires identifying underlying metabolic abnormalities to halt the stone-forming cascade and prevent recurrent morbidity. In accordance with European Association of Urology (EAU) Guidelines, evaluation and preventive medical management are stratified based on patient-specific risk profiles.

---

Indications for Comprehensive Metabolic Evaluation

Not all stone formers require an exhaustive metabolic workup. A first-time former with an uncomplicated, spontaneously passed small calcium oxalate calculus without risk factors is classified as a low-risk stone former and requires basic evaluation including reliable stone analysis (infrared spectroscopy or X-ray diffraction) and laboratory screening (serum electrolytes, creatinine, calcium, uric acid, and urinalysis with dipstick and microscopy) alongside general dietary advice.

Conversely, a comprehensive metabolic evaluation is strictly indicated in high-risk stone formers:

Clinical and Demographic Risk Factors

• Recurrent stone formation (two or more lifetime stone episodes).
• Early onset / pediatric stone disease (presentation at age $< 18$ years).
• Solitary kidney or single functioning kidney (where obstruction threatens anephric renal failure).
• Bilateral or multiple concurrent calculi.
• Nephrocalcinosis (medullary or cortical calcification).
• Positive family history of urolithiasis in first-degree relatives.
• Residual stone fragments following surgical intervention.

Specific Stone Compositions

• Non-calcium stone compositions: Any patient forming uric acid, cystine, or infection (struvite) calculi.
• Unfavorable calcium variants: Brushite-containing stones, without a >50% composition requirement.

Systemic Diseases and Secondary Predispositions

• Primary Hyperparathyroidism (PHPT) (autonomous parathyroid adenoma driving hypercalcemia, hypercalciuria, and hypophosphatemia).
• Distal Renal Tubular Acidosis (Type 1 dRTA) (impaired distal hydrogen ion excretion causing metabolic acidosis, hypercalciuria, and hypocitraturia with inadequately acidic urine).
• Malabsorptive Gastrointestinal Disorders: Crohn's disease, ulcerative colitis, extensive small bowel resection, chronic pancreatitis, and bariatric surgery (especially malabsorptive procedures such as Roux-en-Y gastric bypass and biliopancreatic diversion).
• Gout and Myeloproliferative Disorders.
• Sarcoidosis and Vitamin D Hypervitaminosis.
• Anatomical abnormalities predisposing to urinary stasis (horseshoe kidney, pelviureteric junction obstruction, medullary sponge kidney, calyceal diverticula).

---

Protocol for 24-Hour Urine Collection

The cornerstone of comprehensive metabolic evaluation is the quantitative 24-hour urine analysis.

Collection Timing and Preconditions

• Stable Ambulatory Conditions: The collection must be conducted during the patient's normal, everyday lifestyle, occupational routines, and habitual, unrestricted diet.
• Timing After an Acute Episode: Collect no earlier than 20 days, preferably around three months, when stable, free of infection and on the usual diet/fluid intake. Acute illness, renal dysfunction and temporary treatment changes can make the result unrepresentative.
• Mandatory Replicate Testing: EAU Guidelines mandate at least two consecutive 24-hour urine collections. A single collection exhibits high intra-individual variability (up to 30% day-to-day fluctuation in urinary sodium, calcium, and volume due to dietary variations).

Validation of Collection Completeness

Before interpreting solute excretion, the clinician must confirm that the 24-hour collection is neither under-collected (falsely low solute totals) nor over-collected (falsely inflated solute totals). This is achieved by assessing 24-hour creatinine excretion, which is excreted at a relatively constant daily rate proportional to skeletal muscle mass:

• Adult Males: Approximately 18–25 mg/kg/day (0.16–0.22 mmol/kg/day), or 11.1–15.5 mmol/day for a 70kg man.
• Adult Females: Approximately 15–20 mg/kg/day (0.13–0.18 mmol/kg/day), or 8.0–10.6 mmol/day for a 60kg woman.

Unexpected creatinine excretion prompts a check of collection duration, missed voids, body size and muscle mass. Repeat a demonstrably incomplete collection; a low value alone does not prove under-collection.

Adult Urinary Measurements and Clinical Interpretation

1. Urine Volume: General prevention aims for >2.5 L/day; adjust fluid intake to losses and clinical circumstances.
2. Calcium: EAU lists 5 mmol/day (~200 mg/day) and 8 mmol/day (~320 mg/day) as limits for attention/treatment assessment. Calciuria is continuous; interpret it with recurrence and the full urinary profile when choosing therapy.
3. Oxalate: >0.40 mmol/day is increased;0.40–0.50 is mild hyperoxaluria, >0.50 suggests secondary/enteric causes, and values mostly>1.0 suggest primary hyperoxaluria. Use the clinical context rather than one value alone.
4. Citrate: Hypocitraturia is <1.7 mmol/day in men and <1.9 mmol/day in women (approximately 327 and 365 mg/day).
5. Uric Acid: Hyperuricosuria is >4 mmol/day in women and >5 mmol/day in men (approximately 672 and 841 mg/day).
6. Sodium: Interpret urinary sodium as a dietary marker. A general dietary target of 4–5g NaCl/day corresponds to approximately 1.6–2.0g sodium or 68–86 mmol sodium;150 mmol sodium is approximately 3.45g sodium or 8.8g NaCl.
7. Other Measurements: Magnesium, potassium, phosphate and ammonium as appropriate.
8. Urine pH: Use fresh samples across the day when monitoring alkalinization. Persistent pH<5.5 favors uric acid stones;24-hour pH>6.2 with fasting second-morning pH>5.8 suggests RTA after excluding infection. Persistent pH>7 raises concern for infection.

---

Targeted Medical and Dietary Preventive Therapies

Preventive therapy must address the specific underlying chemical derangement identified on metabolic profiling.

1. General Fluid and Lifestyle Recommendations (All Stone Formers)

• High Fluid Intake: Maintain high diuresis such that daily urinary output exceeds 2.5 L/day. Fluid should be distributed evenly throughout the 24-hour day, including a glass of water before retiring to bed and upon nocturnal awakenings, countering physiological nighttime concentrated antidiuresis.
• Fluid Selection: Neutral-pH water, mineral water rich in bicarbonate and magnesium, and diluted citrus juices. Avoid sugar-sweetened beverages and cola drinks rich in phosphoric acid.
• Balanced Nutrition: Normalization of body mass index, Mediterranean-style diet rich in vegetables and fiber, avoidance of excessive animal protein ($0.8 - 1.0$ g/kg/day), and strict restriction of dietary sodium ($< 4 - 5$ g/day NaCl).

2. Idiopathic Hypercalciuria

Hypercalciuria is the single most common metabolic defect in calcium stone formers (present in 40–60%).

• Dietary Sodium Restriction: Renal tubular reabsorption of calcium in the proximal convoluted tubule is passively coupled to sodium reabsorption. High dietary sodium suppresses proximal sodium reabsorption, directly increasing distal delivery and urinary calcium excretion. Restricting sodium intake (generally 4–5g NaCl/day, approximately 1.6–2.0g sodium) significantly reduces urinary calcium excretion.
• Thiazide Diuretics (First-Line Pharmacotherapy):
  • Agents: Hydrochlorothiazide (25–50 mg daily), Chlorthalidone (25–50 mg daily), or Indapamide (2.5 mg daily).
  • Mechanism: Thiazides inhibit the $Na^+/Cl^-$ cotransporter (NCC) in the early distal convoluted tubule. The resulting mild extracellular volume contraction activates proximal tubular sodium and passive calcium reabsorption, while simultaneously stimulating active distal transcellular calcium uptake via epithelial calcium channels (TRPV5) and basolateral $Na^+/Ca^{2+}$ exchangers. Urinary calcium excretion falls by 30–50%.
  • Monitoring: Check renal function, electrolytes and metabolic adverse effects. Hypokalemia can promote hypocitraturia; correct potassium deficiency and add citrate when indicated rather than mandating combination therapy for everyone. Counsel patients taking hydrochlorothiazide about skin surveillance and review use if there is previous skin cancer.

3. Hypocitraturia & Uric Acid Stones: Urinary Alkalinization

Citrate is an endogenous inhibitor of crystallization. Proximal tubular cells reabsorb citrate via the sodium-dicarboxylate cotransporter 1 (NaDC-1). Intracellular acidosis (caused by systemic acidosis, hypokalemia, or excessive animal protein consumption) stimulates NaDC-1, clearing citrate from the tubular fluid and producing hypocitraturia.

• Potassium Citrate (First-Line Alkalinizing Agent):
  • Dosing: 30 to 60 mEq/day (divided into 2 to 3 doses taken with meals or at bedtime).
  • Mechanism: Citrate is metabolized in the liver to bicarbonate, providing an alkaline load that corrects systemic and renal intracellular acidosis, downregulating NaDC-1 and restoring urinary citrate excretion. Concurrently, the excreted bicarbonate alkalinizes the urine.
  • Target Urinary pH:
    • Calcium stone formers: Individualize alkali to citrate excretion, urine pH and calcium-phosphate risk; pH 6.2–6.8 is not a guarantee against phosphate precipitation.
    • Uric Acid: For prevention, EAU's metabolic algorithm targets pH 6.2–6.8. For active oral dissolution, the chemolysis section targets pH 7.0–7.2, with home pH checks and clinical/imaging follow-up. Dissolution is possible, not assured; relieve clinically significant obstruction when required.

    • Warning

      Avoid overtreatment with urinary pH $> 7.2 - 7.5$, as this induces de novo crystallization of calcium phosphate (apatite or brushite).

• Choice of Alkali: Potassium citrate is commonly preferred, but sodium bicarbonate is an accepted alternative, including for hypocitraturia and uric acid chemolysis. Consider sodium load, urinary calcium, serum potassium and renal function; sodium alkali does not automatically cancel all treatment benefit.
• Hyperuricosuria & Gouty Diathesis: For hyperuricosuric stone formers, use allopurinol as first-line urate-lowering treatment (often 100–300 mg/day, adjusted to renal function); febuxostat 80 mg/day is a second-line option. Hyperuricemia alone does not replace assessment of urine pH and uric acid excretion; uric acid stones primarily require alkalinization.

4. Enteric Hyperoxaluria

Seen characteristically in patients with Crohn's disease, extensive ileal resection, chronic malabsorption, or following bariatric surgery (Roux-en-Y gastric bypass):

+------------------------------------------------------------------------------------------------+
|                               ENTERIC HYPEROXALURIA CASCADE                                    |
|                                                                                                |
|  Malabsorption of Dietary Fats                                                                 |
|  --> Unabsorbed free fatty acids bind intraluminal calcium (saponification)                    |
|  --> Dietary calcium is consumed; cannot bind dietary oxalate into insoluble precipitate       |
|  --> Free, unbound, soluble oxalate reaches the colon in massive concentrations               |
|  --> Malabsorbed bile salts & fatty acids increase colonic mucosal permeability               |
|  --> Hyper-absorption of oxalate across colonic mucosa into systemic circulation              |
|  --> Marked renal hyperoxaluria (> 0.5 - 1.0 mmol/day) + chronic diarrheal hypocitraturia      |
+------------------------------------------------------------------------------------------------+

• Treatment Protocol:
  1. Aggressive oral fluid hydration ($> 3.0$ L/day).
  2. Dietary fat restriction (reduces saponification) and restriction of high-oxalate foods (spinach, rhubarb, nuts, chocolate, beetroot, black tea).
  3. Oral Calcium Carbonate or Calcium Citrate (500–1,000 mg) taken strictly with meals: The supplementary calcium binds free oxalate within the gut lumen, precipitating insoluble calcium oxalate that is excreted harmlessly in feces.
  4. Potassium Citrate: To correct concomitant metabolic acidosis and profound hypocitraturia resulting from gastrointestinal bicarbonate wasting.

5. Cystinuria

Cystinuria is an aggressive hereditary disease with rapid lifelong calculus recurrence.

• Step 1: Aggressive Hydration: Target urine volume $>3$ L/day in adults, with fluids spread across day and night. Individualize the volume and timing to maintain adequate cystine dilution throughout the day and night. The objective is to dilute urinary cystine concentration below its solubility threshold of $< 1.0$ mmol/L ($< 250$ mg/L).
• Step 2: Urinary Alkalinization: Administer Potassium Citrate (or sodium bicarbonate) titrated to achieve and maintain a urinary pH consistently $> 7.5$ (ideally 7.5–8.0). Cystine solubility doubles between pH 7.0 and pH 7.5. Avoid pH $> 8.0$ to prevent calcium phosphate precipitation.
• Step 3: Dietary Restriction: Sodium restriction ($< 2$ g/day; sodium reabsorption is linked to cystine excretion) and animal protein restriction (methionine is the dietary precursor of cystine).
• Step 4: Thiol-Binding Drugs (Second-Line Pharmacotherapy):
  • Indicated when stones recur or urinary cystine excretion exceeds 3.0 mmol/day (approximately 720 mg/day) despite maximal hydration and alkalinization.
  • Agents: Tiopronin (alpha-mercaptopropionylglycine, 800–1,200 mg daily in divided doses) or D-penicillamine.
  • Mechanism: Thiol drugs contain an active sulfhydryl ($-SH$) group that engages in disulfide exchange with cystine, cleaving the insoluble cystine molecule into a cysteine-drug mixed disulfide complex that is 50 times more soluble than cystine.
  • Toxicity: Significant adverse event profile requiring close monitoring: membranous nephropathy with heavy proteinuria (mandatory regular urinalysis for proteinuria), allergic skin rash, fever, arthralgia, leukopenia, thrombocytopenia, and hepatotoxicity.

Summary of Metabolic Abnormalities and Medical Therapies